ArticleBMC cancer2010
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Therapeutic radiotherapy for giant cell tumor of the spine: a systemic review.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2015Pooled it
- Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.The oncologist · 2019Trial
- Delayed Metachronous Multicentric Giant Cell Tumor of Bone after a 16-Year Disease-Free Interval: A Case Report.Journal of orthopaedic case reports · 2026Article
- "A Giant Shoulder": Proximal Humerus Giant Cell Tumor Managed With Extended Curettage and Proximal Humerus Internal Locking System Plating with Fibular Strut Graft - A Case Report.Journal of orthopaedic case reports · 2026Article
- Intraosseous tumours of the knee.Skeletal radiology · 2026Review
- A Rare Case of Giant Cell tumor of Bone in Distal Tibia.Journal of orthopaedic case reports · 2026Article
- Soft tissue recurrence in giant cell tumor of Bone: A comprehensive review of pathogenesis, imaging features, and clinical management.Journal of bone oncology · 2025Review
- Malignant Giant Cell Tumor of Bone: A Study of Clinical, Pathological, and Prognostic Profile from One Single Center.Bioengineering (Basel, Switzerland) · 2025Article
- Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB11-C1 and NCC-GCTB12-C1.Human cell · 2025Article
- Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Giant Cell Tumor of Soft Tissue: An Updated Review.Journal of clinical medicine · 2024Review
- Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal.Journal of bone oncology · 2024Article
- Primary Hyperparathyroidism With Brown Tumor of the Mandible Misdiagnosed as a Giant Cell Tumor: A Case Report.Cureus · 2024Article
- Article
- Contiguous Lumbar Vertebral Involvement with Vertebral Collapse in Giant Cell Tumor: A Usual Tumor with an Unusual Presentation.Journal of laboratory physicians · 2023Article
- Mid-term results of giant cell tumours with pathologic fractures around the knee: a multicentre retrospective study.BMC musculoskeletal disorders · 2022Article
- Premalignant Conditions of Bone.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2022Article
- Article
- Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.Journal of bone oncology · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts.
methodIn this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs.
resultsTreatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro.
conclusionOur findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.